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Tumor cellsThe role of p53 as modulator of OxPhos and glycolysis was analyzed in HeLa-L (cells containing negligible p53
protein levels) and HeLa-H (p53-overexpressing) human cervix cancer cells under normoxia and hypoxia. In
normoxia, functional p53, mitochondrial enzyme contents,mitochondrial electrical potential (ΔΨm) and OxPhos
ﬂux increased in HeLa-H vs. HeLa-L cells; whereas their glycolytic enzyme contents and glycolysis ﬂux were
unchanged. OxPhos provided more than 70% of the cellular ATP and proliferation was abolished by anti-
mitochondrial drugs inHeLa-H cells. In hypoxia, both cell proliferationswere suppressed, but HeLa-H cells exhib-
ited a signiﬁcant decrease in OxPhos protein contents, ΔΨm and OxPhos ﬂux. Although glycolytic function was
also diminished vs. HeLa-L cells in hypoxia, glycolysis provided more than 60% of cellular ATP in HeLa-H cells.
The energy metabolism phenotype of HeLa-H cells was reverted to that of HeLa-L cells by incubating with
piﬁthrin-α, a p53-inhibitor. In normoxia, the energy metabolism phenotype of breast cancer MCF-7 cells was
similar to that of HeLa-H cells, whereas p53shRNAMCF-7 cells resembled the HeLa-L cell phenotype. In hypoxia,
autophagy proteins and lysosomes contents increased 2–5 times in HeLa-H cells suggesting mitophagy activa-
tion. These results indicated that under normoxia p53 up-regulatedOxPhoswithout affecting glycolysis, whereas
under hypoxia, p53 down-regulated both OxPhos (severely) and glycolysis (weakly). These p53 effects appeared
mediated by the formation of p53-HIF-1α complexes. Therefore, p53 exerts a dual and contrasting regulatory
role on cancer energy metabolism, depending on the O2 level.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
p53 is a key transcriptional factor modulating different cellular pro-
cesses associated with tumor suppression mechanisms i.e., DNA and
genotoxic damages; cell cycle regulation and proliferation; apoptosis;
and nutritional stress [1]. An additional role of p53 as a glycolytic and
oxidative phosphorylation (OxPhos) key modulator has recently
emerged [2]. For glycolysis under normoxia, it has been described that
p53 (i) increases (70%) the TIGAR mRNA content (whose enzymeATPS, ATP synthase; Fru2,6BP,
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uez-Enríquez).activity decreases the PFK-1 activator, Fru2,6BP) in colon HCT116 carci-
noma, and U2OS osteosarcoma [3]; and (ii) decreases (30–50%) the
GLUTs and PGAM mRNA and protein contents in p53-transformed
mouse embryonic ﬁbroblast and osteosarcoma cells [4,5], which is asso-
ciated with a moderate diminution (20–40%) in the glucose uptake and
glycolytic ﬂux. Also p53 promotes the ubiquitination and degradation of
several glycolytic proteins such as PGAM and GLUTs in mouse embryo
ﬁbroblasts [6].
On the contrary, p53 increases expression of several genes coding for
mitochondrial proteins such as the cytochrome c oxidase assembling
protein SCO2 (6–10 times) and glutaminase 2 (12 times) in HepG2
and HCT116 tumor cell lines, increasing (37–50%) their oxygen con-
sumption rates [7,8]. Also, p53 represses the transcription of pyruvate
dehydrogenase kinase 2 (PDK2) involved in PDH inactivation in MCF-
7 andHCT116 cancer cell lines [9]. In addition, two proteins directly reg-
ulated by p53, AIF (apoptosis inhibitor factor) and Parkin (a RBR E3
ubiquitin protein ligase) are involved in protein expression and func-
tioning of NADH dehydrogenase (respiratory chain complex I) and
PDH activation (35%) [10,11] which in turn, increase OxPhos ﬂux.
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on energy pathways have not been elucidated in tumor cells, it has
been suggested for non-tumor cells that p53 increases mtDNA stabi-
lization and transcription of several mitochondrial genes (COX I, II
and III subunits, ATPS subunit 6 and cytochrome b) codiﬁed by
mtDNA [12].
It was recently found in breast MCF-7 carcinoma (i.e., cells withwild
type-p53 protein content) that acute and severe hypoxia (0.1% atmo-
spheric O2, 24 h) induced (i) a signiﬁcant decrement (20–70%) in the
contents and activities of several OxPhos enzymes (COXIV, 2OGDH
and glutaminase-L) and ﬂux; and (ii) p53 overexpression. However, in
cervix HeLa cells (i.e., cells with negligible p53 protein content) acute
and severe hypoxia did not signiﬁcantly affect mitochondrial metabo-
lism. These observations suggested that OxPhos transcriptional regula-
tion by p53 was dependent on the O2 level [13].
Therefore, to assess the hypothesis that the O2 status inﬂuences p53
regulation of cancer energy metabolism, the mitochondrial and glyco-
lytic metabolism was evaluated in two human cancer cell lines, cervix
carcinoma stage IV HeLa cells and breast cancer stage III MCF-7, by
performing an integral analysis of the mRNA and protein contents,
and pathway ﬂuxes. The HeLa parental strain (here referred as HeLa-L
cells) has a constitutively negligible p53 protein content due to the spe-
ciﬁc proteolytic activity of HPV E1 [14]; these cells were transfected to
overexpress the wild type sequence of p53 (HeLa-H cells). On the
other hand, the wild type MCF-7 cells, which express non-mutated
p53, were subjected to p53 down-regulation by antisense methods
(p53shMCF7 cells). Besides geneticmanipulation, selective chemical in-
hibition of p53 function with piﬁthrin-α was also performed in both
HeLa-H and HeLa-L as well as in MCF7 cells. The results of the present
study contribute to the understanding of the cancer energy metabolism
changes associated with p53 function, providing guidance in the design
of more appropriated targeted clinical treatment strategies.2. Materials and methods
2.1. Cell culture
All cell types were grown in Dulbecco-MEM medium (Gibco; Rock-
ville, MD, USA) supplementedwith 10% fetal bovine serum and incubat-
ed in 5% CO2 at 37 °C. Genotyping of the parental strains at INMEGEN,
México, indicated that the HeLa cell line shared 15 of 16 canonic allelic
markers with the original HeLa clone from the ATCC, whereas theMCF-
7 cell line shared 16 of 16 canonic allelic markers with the original clone
from the same collection. These markers were not changed after p53
overexpression or downregulation in HeLa-H and p53shMCF-7 cells,
respectively. For hypoxia, cells were placed in a humidiﬁed hypoxic in-
cubator chamber (BillupsRothenberg; CA, USA) at 0.1% atmospheric O2
and incubated for 24 h [13].2.2. p53 expression in HeLa cells and p53 silencing in MCF-7 cells
(p53shMCF-7 cells)
p53 was overexpressed in HeLa-L cells with 0.5 μg of the plasmid
pCMV-Neo-BamWT (provided by Dr. Bert Vogelstein at Johns Hopkins
University, Baltimore, MD, USA), and a commercial cell transfection
assay (SA Biosciences; Ontario, Canada) following the manufacturer in-
struction. After transfection, 1200 μg G418 antibiotic/mL was added for
selection of stably-transfected cells.
Speciﬁc RNA silencing kit (Sure Silencing RNA Interference Plasmid-
Based; SA Biosciences) was employed. p53 silencing in MCF-7 cells was
performed with the silencing plasmid (0.5 μg) and lipofectamine
2000™, following the manufacturer instructions. After transfection,
800 μg G418 antibiotic/mL was added for selection of stably-
p53shRNA cells.2.3. mRNA content analyses
Total RNA was extracted by using the RNeasy Protect Cell Mini Kit
(Qiagen; Valencia, CA, USA) according to themanufacturer instructions.
The RNA (4 μg) was converted to cDNA by using a Super Script
First-Strand Synthesis System (Invitrogen; Carlsbad, CA, USA). The
QuantiTect SYBR Green PCR kit (Qiagen) was used for qRealTime-PCR
analysis using 600 ng of template cDNA, the primers showed in
Table S1 and following the manufacturer instructions. PCR was per-
formed in a StepOne Real-Time PCR System (Applied Biosystems;
Grand Island, NY, USA) with the following cycling conditions: 95 °C
for 15 min, followed by 40 cycles of 95 °C for 15 s, 60 °C for 30 s and
72 °C for 30 s. Actin was used as a house-keeping reference gene. Anal-
ysis was performed in at least three independent biological samples for
each experimental condition. Folds ofmRNA content changes in HeLa-H
cells vs. HeLa-L cells under normoxia were determined by the 2-ΔΔCt
method [15].
2.4. Protein content and immunoprecipitation analyses
To determine protein contents by Western blot, cellular extracts
were processed and analyzed as it was described in [13] using antibod-
ies for p53, p53 (P-Ser 15), NOXA, PUMA, HIF-1α, TIGAR, GLUT1, GLUT3,
HK-II, PFK-1, LDH-A, ND-1, COX-IV, PDH, 2OGDH, GA-L, ATPS, ANT,
BNIP3, Foxo3a, P-Foxo3a, Atg3, LAMP1, XIAP, active caspase 3 and
β-actin (Santa Cruz; CA, USA) at 1:1000–2000 dilutions. The corre-
sponding secondary antibodies (at 1:2000 dilutions) and ECL-plus
detection system (Amersham; Buckinghamshire, UK) were used for de-
tection. Densitometric analysis was performed using the Image J Soft-
ware (NIH; Bethesda, MD, USA).
To assess the p53-HIF1α interaction, both proteins were immuno-
precipitated with antibodies against HIF-1α or IgG1 (1 μg) for 1 h plus
protein A (Sigma-Aldrich, St. Louis, MO). p53 was detected with anti-
p53 antibody (Santa Cruz) following manufacturer instructions.
2.5. OxPhos and glycolysis ﬂuxes
For glycolysis and OxPhos, cells were incubated in Krebs-Ringer
buffer (125 mM NaCl, 5 mM KCl, 25 mM HEPES, 1.4 mM CaCl2, 1 mM
KH2PO4, 1mMMgCl2, pH7.4)with 5mMglucose at 37 °C. Produced lac-
tate was determined as previously described in [16]. Oxygen consump-
tion sensitive to oligomycin (5 μM) was determined with a Clark-type
O2 electrode as previously described [13].
2.6. Mitochondrial transmembrane electrical potential (ΔΨm)
ΔΨm was determined in cells incubated with 0.25 μM rhodamine
6G at 37 °C in air-saturated Krebs-Ringer buffer and monitored with
a Shimadzu spectroﬂuorophotometer RF-5301PC (Tokyo, Japan) at
λexcitation of 480 nm and λemission of 565 nm [17]. At the end of each
experiment, the uncoupler CCCP (5 μM) was added to establish the
magnitude of the ﬂuorescence signal derived from mitochondria.
2.7. Mitochondrial and lysosomal contents
Cells were cultured in glass bottom microwell 35-mm Petri dishes
(MatTek; Ashland, MA, USA) with MitoTracker Green (MTG, 0.5 μM)
and LysoTracker Red (LTR, 0.5 μM). Time series of confocal images
were collected every 1 to 2 min with a Zeiss LSM 510 meta inverted
laser scanning confocal microscope (Carl Zeiss; Oberkochen,
Germany) using 63X oil 1.4 N.A. plan apochromat objective lens. LTR
λexcitation 543 nm was provided by a helium/neon laser and λemission of
560 nm was used. MTG λexcitation 488 nm was provided by an
argon laser and λemission of 500–550 nm was used. Laser excitation
energy was attenuated 1000-fold to minimize photobleaching and
photodamage [18].
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Cells were ﬁxed with cold 4% paraformaldehyde and permeabilized
with 0.1% (w/w) Triton X-100 at room temperature. Afterwards, cells
were incubated with p53 or p53 (P-Ser 15) primary antibodies
(Abcam; Cambridge, MA, USA) at 1: 200 dilution, as well as with 15 μg
DAPI/mL (Abcam) and revealed with Alexa488 (Abcam). p53 ﬂuores-
cence was detected by using an EVOS®FL Auto Cell Imaging System
(Life Technologies; Grand Island, NY, USA).
2.9. Apoptosis assays
Cellular apoptosis was monitored with 25 ng Annexin V-FITC plus
250 ng propidium iodide and analyzed using a FACSCalibur ﬂow
cytometer (Becton Dickinson; San Jose, CA, USA). Analysis was carried
out for 10 000 events using the Summit V4.3 software (BeckmanCoulter
Inc.; Fullerton, California, USA).
3. Results
3.1. Overexpressed p53 in HeLa-H cells is active
To assess for the presence of p53 in HeLa-H cells, the p53 mRNA
(Table S2) and protein contents (Fig. 1A) were determined and com-
pared with those of HeLa-L cells in both normoxia and hypoxia. Indeed,
the p53 mRNA (2-times) and both phosphorylated (3-times) and non-
phosphorylated (4-times) p53 protein levels were signiﬁcantly higher
in HeLa-H than in HeLa-L cells. Thus, HeLa-H cells overexpressing p53
were able to overcome the inhibition of endogenous p53 engendered
by HPV infection. In addition, immunoﬂuorescence staining of HeLa-H
cells showed that phosphorylated p53 was exclusively localized into the
nucleus, its site of transcriptional action, whereas non-phosphorylated
p53 was preferentially localized in the cytosol under both normoxia and
hypoxia (Fig. 1B).Fig. 1. p53 overexpression in HeLa-H cells is functionally active (A) Representative Wester
normoxia (Nor) and 24 h hypoxia (Hyp). For clarity, double normalization vs. actin and normox
of apoptosis; TIGAR, TP53-induced glycolysis and apoptosis regulator. (B) Subcellular localiza
p53 and DAPI-loaded nuclear immuno-ﬂuorescence signals were determined as described in tTo further demonstrate that overexpressed phosphorylated-p53
(at Ser 15) was active, the p53-downstream protein targets PUMA,
NOXA (Fig. 1A) and TIGAR (Fig. 3A) were determined. As expected,
these protein contents were several times higher in HeLa-H than in
HeLa-L cells. As p53 and the p53-targets PUMA and NOXA (under
normoxia) were undetectable in HeLa-L cells, the data suggested that
the increased level of phosphorylated p53 in HeLa-H cells actually
corresponded to increased p53 activity despite the presence of the E6
oncoprotein. Therefore, these observations indicated that overexpressed
p53 is phosphorylated and functionally active in HeLa-H cells [19,20].
3.2. Effect of p53 onHeLa-L and -H cell growth under hypoxia and normoxia
Although phosphorylated p53 is involved in the cell cycle regulation,
assays of growth in normoxia, with both cells, revealed no statistically
signiﬁcant changes in the speciﬁc growth rates, cellular yields and pop-
ulation doubling time (Fig. 2A). Under hypoxia (0.1%O2), cellular prolif-
eration of both tumor cells was arrested (Fig. 2A), as previously
described forMCF7 andHeLa cells [13]. Signiﬁcant cell deathwas appar-
ent under hypoxia after 24 h for HeLa-H and after 48 h for HeLa-L. Flow
cytometry assays revealed that 24 h hypoxia did not lead to signiﬁcant
cell death by apoptosis (less than 5%) in both cells (Fig. 2B).
To further support the last conclusion both cells were exposed to
cisplatin (CP, 10 μM/24 h), a well-known apoptotic inducer under
normoxia [21]. Indeed, the content of the apoptosis marker active cas-
pase 3 increased (2–3 times) whereas that of the anti-apoptotic XIAP
protein decreased (70–100%) in CP-treated cells vs. nontreated cells
(Fig. 2C). Moreover, the level of caspase 3 under hypoxia in both
HeLa-L and HeLa-H cells was signiﬁcantly lower than that found in
CP-treated cells, suggesting that the arrest of HeLa cell proliferation ob-
served under hypoxia did not involve apoptosis onset, although PUMA
and NOXA protein levels were signiﬁcantly increased in HeLa-H cells
(Fig. 1A). These results clearly indicated that other cell death processes
such as mitophagy were also involved in the lowering of viable cellsn blot of at least three different, independent experiments in HeLa-L and HeLa-H cells in
iawas performed. aP b 0.01 vs. HeLa-H. Abbreviations: PUMA, p53 up-regulatedmodulator
tion of phosphorylated-p53 (ser 15; P-p53) and non-phosphorylated p53 in HeLa-H cells.
he Material and Methods section under normoxia (21% O2) and 24 h hypoxia (0.1% O2).
Fig. 2.HeLa-L and HeLa-H cell growth and non-apoptotic incidence under normoxia (21% O2) and 24 h hypoxia (0.1% O2) (A) HeLa-L (●) and HeLa-H (▲) cells (5 x 105 cells/mL) were
grown inDulbecco-MEMmedium at 37 °C and 21%O2. After 72 h (black arrow), bothHeLa cell cultureswere exposed to hypoxia (Hyp, 0.1%O2, open symbols), or kept under normoxia, for
additional 48 h. Viabilities in normoxic and hypoxic conditionswere 75–90% forHeLa-H andHeLa-L cells; n=3, aP b 0.05 vs. HeLa-H at 72h, Nor. The population doubling level (n), or total
number of times the cells in the population have doubled,was calculatedwith the following equation: n=0.332(logNH− logNI) whereNH represents the number of cells harvested at the
end of the growth period and NΙ represents the number of inoculated cells at the beginning of the growth curve [66]. (B) Cytometry ﬂux analysis: R2 area represents the percentage of
cells undergoing necrosis; R3 area represents the percentage of cells in late apoptosis; R4 area represents the percentage of living cells; and R5 area represents the percentage of cells
initiating apoptosis. Apoptosis was determined by using the Annexin V-FITC assay. (C) Representative Western blot of at least three different independent experiments in HeLa-L
and HeLa-H cells in normoxia (Nor) and 24 h hypoxia (Hyp), except for Casp3 (n= 2). Cisplatin (CP)was added at 10 μM for 24 h only under normoxia. For clarity, double normalization
vs. actin and normoxiawas performed. aP b 0.01 vs. Nor. The contents of XIAP and LAMP1were revealed and analyzed in the same PVDF-membrane, like all otherWestern blots performed
in the present paper. However, for clarity in this particular case, spliced images of these proteins are shown, to keep the same sequence of cell type and experimental condition.
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such as LAMP1 suggested that apoptosis induction by CP was also
accompanied by autophagy activation in HeLa-L and HeLa-H cells
(Fig. 2C).
3.3. Effect of p53 expression on mRNA and protein contents, and ﬂuxes of
OxPhos and glycolysis in HeLa cells under normoxia
Under normoxia, the presence of phosphorylated p53 in HeLa-H
cells (vs. HeLa-L cells) induced a doubling in the protein contents of
HIF-1α and LDH-A (Figs. 3A and S1A), which correlated with an in-
crease (2-times) in the total lactate production (Fig. 4A), despite signif-
icant decrements in GLUT1 and GLUT3 contents (Figs. 3A and S1A).
However, after correcting for lactate production in the presence of the
glycolytic inhibitor 2-deoxyglucose (2DG), the true glycolytic ﬂux was
similar in both HeLa-L and HeLa-H cells (Fig. 4B). It is noted that the
non-glycolytic lactate production (i.e., lactate produced in the presence
of 2DG) was markedly higher in HeLa-H cells (Fig. 4B) and wasabolished (N95%) by the respiratory complex 1 inhibitor rotenone, sug-
gesting that this lactate was generated via glutaminolysis. It is worth
recalling that glutaminolysis fully depends on mitochondrial metabo-
lism where NAD(P)H, generated by glutamine oxidation at the gluta-
mate and 2-oxoglutarate dehydrogenases and malic enzyme levels, is
further re-oxidized by the respiratory complex 1 [22,23].
Regarding OxPhos under normoxia, signiﬁcant increments in the
contents of several proteins (Figs. 3B and S1B), ﬂux (1.6-fold; Fig. 4B)
and mitochondrial membrane potential (ΔΨm, 1.4-fold; Fig. S2) were
detected under normoxia in HeLa-H cells vs. HeLa-L cells. The mRNA
levels (Table S2) were unvaried (COXIV, 2OGDH, and ATPS) or signiﬁ-
cantly lower (ND1) in HeLa-H vs. HeLa-L cells showing no correlation
with the protein contents (Fig. S1B). The rate of oligomycin-resistant
respiration (i.e., O2 consumption not associated to OxPhos) was similar
for both cell types, andwas almost completely blocked by cyanide (data
not shown), indicating that the majority of total cellular O2 consump-
tion (Fig. 4A) was associated to the respiratory chain activity but not
to extramitochondrial reactions.
Fig. 3. Energy pathways-related proteins in HeLa-L and HeLa-H cells (A) Representative Western blot of transcription factors and glycolytic-related proteins in HeLa-L and HeLa-H cells
under normoxia (Nor, 21% O2) and 24 h hypoxia (Hyp, 0.1% O2); double normalization vs. actin and normoxia was performed. n = 3, a P b 0.01 vs. HeLa-H. (B) Representative Western
blot of OxPhos-related proteins in HeLa-L and -H cells under normoxia (Nor, 21% O2) and 24 h hypoxia (Hyp, 0.1% O2), double normalization vs. actin and normoxia was performed.
n = 3, a P b 0.01 vs. HeLa-H; b P b 0.05 vs. HeLa-H. Abbreviations: ATPS, ATP synthase; ANT, adenine nucleotide translocator; COXIV, cytocrome c oxidase; GA-L, glutaminase- L;
GLUT1, glucose transporter-1; GLUT3, glucose transporter-3; HIF-1α, hypoxia inducible factor-alpha; HKII, hexokinase-II; KC, Krebs cycle; LDH-A, lactate dehydrogenase-A, ND1, NADH
dehydrogenase; PDH, pyruvate dehydrogenase; PFK-1, phosphofructokinase-1; PS, phosphorylation system; RC, respiratory chain; TIGAR, TP53-inducible-glycolysis and apoptosis regu-
lator; 2OGDH, 2-oxoglutarate dehydrogenase.
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OxPhos and glycolysis in HeLa under hypoxia
Under severe and acute hypoxia HeLa-L cells showed (a) increased
contents of HIF-1α and glycolytic proteins GLUT1, HKII, and LDH-A, a
decreased TIGAR content, and unchanged GLUT3 and PFK-1 levels
(Fig. 3A); and (b) increased glycolysis ﬂux (Fig. 4B) vs. normoxia. Simi-
lar observations have also been documented for several cancer cell lines
such asMCF-7,MDA-MB-453, HeLa, AS-30D hepatoma, and sarcoma 37
[24,25]. In marked contrast, in HeLa-H cells under hypoxia the HIF-1α
and glycolytic protein contents were unchanged, except for GLUT1
which increased (Fig. 3A), and pathway ﬂux actually decreased
(Fig. 4B) vs. normoxia.
Furthermore, the presence of a high level of functional and phosphor-
ylated p53 inHeLa-H cells sensitized OxPhos to hypoxia-induced damage
as revealed by (a) the decrease in the protein contents (30–93%) of sever-
al enzymes of the respiratory chain (ND1, COXIV), Krebs cycle and
anaplerotic reactions (2OGDH, PDH), and OxPhos phosphorylationsystem (ANT, ATPS) (Fig. 3B), as also documented for MCF-7 carcinoma,
a breast cancer cell line harboring relatively high p53 levels [13]; and
(b) the severe decrease in OxPhos ﬂux and ΔΨm (Figs. 4B and S2). On
the contrary, in HeLa-L cells OxPhos protein contents (Fig. 3B), and path-
way ﬂux (Fig. 4B) were unchanged (ND1, COXIV, PDH, ATPS) or even
increased (2OGDH, GA-L, ANT) (vs. normoxia); in these last cells, a pro-
nounced decrease in ΔΨm (Fig. S2) was the only detected change in the
mitochondrial function induced by hypoxia. Under hypoxia, the rate of
oligomycin-resistant respiration changed from 2 nanogram atoms
oxygen/min/mg protein in HeLa-L cells to 8 nanogram atoms oxygen/
min/mg protein in HeLa-H cells, and again was almost completely
blocked by cyanide in both cell types (data not shown).
The changes in the OxPhos and glycolysis protein contents, ΔΨm,
and ﬂuxes in HeLa-H and HeLa-L under hypoxia, as well as normoxia,
did not correlate with their corresponding mRNA contents determined
after 24 h (Table S2), suggesting that transcriptional changes occurred
at an early time whereas post-translational changes occurred after
24 h, independently of the O2 level. Similar observations have been
Fig. 4. Energy metabolism proﬁle in HeLa-L and HeLa-H cells (A) Total oxygen consumption and lactate production. (B) OxPhos, Glycolysis and glutaminolysis ﬂuxes. OxPhos ﬂux repre-
sents the 5 μMoligomycin-sensitive respiratory rate. The glycolysisﬂuxwas calculated as the lactate production in thepresence of 10mM2DG (the glucose concentration in the incubation
medium was 5 mM); glutaminolysis ﬂux was determined as the lactate production resistant to 2DG and sensitive to 5 μM rotenone. PFT-α was 10 μM in incubations for 24 h. (C) ATP
supply. For calculations, it was assumed that 1 mol ATP is produced permol glycolytic lactate formed; and the rate of OxPhos ﬂux was multiplied by a P/O ratio of 2.5. The data shows
the mean ± SD of three independent preparations assayed, except where otherwise indicated. aP b 0.01 vs HeLa-L, Nor; bP b 0.01 vs HeLa-H, Nor; cP b 0.01 vs HeLa-L, Hyp; dP b 0.01 vs
HeLa-H, Hyp; eP b 0.05 vs HeLa-H, Nor + PFT-α; fP b 0.01 vs MCF-7, Nor; gP b 0.01 vs p53shMCF-7, Nor. Abbreviations: OxPhos, oxidative phosphorylation; 2DG, 2-deoxyglucose;
PFT-α, piﬁthrin-α; p53shMCF-7, p53-silenced MCF-7 cells; Nor, normoxia; Hyp, hypoxia (0.1% O2, 24 h).
Table 1
IC50 values of the cell growth for glycolytic and OxPhos inhibitors in HeLa-L and HeLa-H
cells.
Anti-mitochondrial drugs HeLa-L HeLa-H
CasII-gly (nM) 300 ± 20 (6) 40 ± 8⁎ (6)
Oligomycin (μM) 57 ± 5(6) 30 ± 2.5⁎ (3)
α-TOS (μM) N100 (3) 46 ± 22 (3)
α-TEA (μM) 23 ± 2 (3) 19 ± 5 (3)
Anti-glycolytic drugs
2DG (mM) 7 ± 3 (6) 15 ± 5⁎⁎ (6)
Gossypol (μM) 268 ± 56 (3) 307 ± 106 (3)
IAA (μM) 504 ± 66 (3) 814 ± 96⁎ (3)
CasII-gly (0.05–1 μM), oligomycin (1–100 μM), α-TOS (1–100 μM), α-TEA (1–100 μM);
gossypol (0.1–1 mM), IAA (0.1–5 mM) or 2DG (1–30 mM) were added at the beginning
of the normoxic HeLa-L and HeLa-H cell cultures and the inhibitor concentration required
to inhibit by 50% the cell growth (IC50) was determined at the 96 h-time point. The exter-
nal glucose concentration in the culture media was 25mM. The data shown represent the
mean ± S.D. of 3 or 6 different assayed preparations.
Abbreviations: CasII-gly, casiopeina II-gly; IAA, iodoacetate; 2DG, 2-deoxyglucose; α-TEA,
α-tocopheryloxyacetate; α-TOS, α-tocopherylsuccinate.
⁎ P b 0.01 vs. HeLa-L.
⁎⁎ P b 0.05 vs. HeLa-L.
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mental conditions [26].
3.5. Role of p53 on the regulation of the cellular ATP supply
The analysis of the energy pathway ﬂux rates revealed that, under
normoxia, p53 increased the energy dependence on OxPhos (61% in
HeLa-L, 70% in HeLa-H; Fig. 4C) with glycolysis playing a minor role. In-
terestingly, a signiﬁcant fraction of the ATP supplied by OxPhos in HeLa-
H cells very likely derived from glutaminolysis (Fig. 4B, C), whereas the
glutaminolysis contribution in HeLa-L cells was negligible, indicating
higher dependence on glutamine oxidation in HeLa-H cells vs. HeLa-L
cells. In contrast, under hypoxia, p53 promoted a higher energy depen-
dence on glycolysis (55% in HeLa-L, 64% in HeLa-H; Fig. 4C). It should be
noted that, although glycolysis was diminished by hypoxia in HeLa-H
cells (vs. normoxia; Fig. 4B), this pathway prevailed as the principal
ATP supplier under hypoxia for these p53-enriched cells (Fig. 4C).
In agreementwith the above-described data under normoxia, growth
of HeLa-H cellswas signiﬁcantlymore sensitive (7.5-fold vs. HeLa-L cells)
to several anticancer and anti-mitochondrial drugs such as the copper-
based drug casiopeinaII-gly (CasII-gly), α-tocopherylsuccinate (α-TOS)
andα-tocopheryloxyacetate (α-TEA) as well as the classical ATPS inhib-
itor oligomycin; and less sensitive to the glycolytic inhibitors 2DG,
iodoacetate and gossypol (Table 1). CasII-gly is a potent OxPhos inhibitor
primarily diminishing the PDH, 2OGDH and SDH activities [27,28]; at
high concentrations (≥ 100 μM), CasII-gly also behaves as a glycolytic in-
hibitor mainly affecting HK activity. α-TOS is an ubiquinone/succinate
analog inhibiting succinate dehydrogenase (respiratory complex II) ac-
tivity and affecting the growth of several breast cancer cells [29]. α-TEAis a vitamin E analogwith strong inhibitory effect on the growth of breast
cancer MDA-MB-435 cells and cancer xenografts in nude mice [30]. 2DG
is a glucose analog that inhibits HPI, HK and GLUT activities diminishing
glycolytic ﬂux [27], iodoacetate primarily reacts with the reactive Cys149
present in GAPDH catalytic center, and gossypol inhibits the
NAD+-dependent enzymes such as GAPDH and LDH [31]. It should
be noted that the oligomycin IC50 value found in both HeLa-L and
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tion (5 μM) required to reveal the OxPhos ﬂux (Fig. 4B). The total cellu-
lar respiration, assayed in a salinemedium,was 80–90% sensitive to 5 μM
or higher oligomycin concentrations. However, in cell proliferation as-
says, culture medium with high fetal bovine serum (i.e., albumin) is
used, which masks the oligomycin effect.
3.6. Energy metabolism in cancer cells with blockage of p53 activity
To further support the role of p53 as an energymetabolismmodula-
tor, glycolysis and OxPhos were assessed in (i) HeLa-H cells incubated
with the selective p53 inhibitor, piﬁthrin-α (PFT-α) [32], and (ii) p53
silenced shMCF-7 cells.
In HeLa-H cells, PFT-α decreased the contents of both phosphorylat-
ed and non-phosphorylated p53 under hypoxia and normoxia (Fig. 5A),
being phosphorylated p53 more sensitive. The p53-target TIGAR was
also decreased by PFT-α, whereas p27 (a non-p53 target) level was un-
altered (Fig. 5A). For all proteins assayed, only one band was observed
except for TIGAR (in normoxia) suggesting protein degradation. Under
normoxia, the presence of PFT-α did not affect the proliferation rate
and yield of HeLa-H cells (Fig. 5B). The severe effect of 24 h hypoxia ar-
resting HeLa-H proliferation was further enhanced by the presence of
PFT-α (Fig. 5B). PFT-α also decreased OxPhos and glutaminolysis ﬂuxes
(Fig. 4B) and ΔΨm (Fig. S2) in HeLa-H cells to levels similar to those of
HeLa-L cells under normoxia, whereas glycolysis remained unchanged.
In contrast, under hypoxia PFT-α restored OxPhos and glycolytic ﬂuxes,
andΔΨm, in HeLa-H cells (Figs. 4B, S2) to levels similar to those of HeLa-
L cells. The re-establishment of the glycolytic ﬂux observed in PFT-α
treated HeLa-H cells correlated with signiﬁcant increases in the levels
of HIF-1α and its glycolytic-targets GLUT1, HKII and LDH (Fig. 5C)
under hypoxia. As a control PFT-α was also assayed in HeLa-L cells,
showing no effects on OxPhos ﬂux and ΔΨm (Table S3), as expected.
On theother hand, in humanbreast cancerMCF-7 cells,whichhave a
relatively high p53 content compared to HeLa-L cells (Figs. 1A and 6A),Fig. 5. Effect of piﬁthrin-α (PFT-α) on p53 function in HeLa-H cells (A) Protein contents of pho
blot (3 assaysmadewith independent cell samples) for total p53, phosphorylated-p53, and TIGA
(n= 3) in the absence (▲,Δ) or in the presence (■,□) of 10 μM PFT-α. Full symbols represent n
72 h. (C) HIF-1α and glycolysis-related protein contents. Western blotting analysis of HIF-1α a
actin was performed. n = 3, a P b 0.01 vs. HeLa-H cells.hypoxia signiﬁcantly (a) diminished the cellular growth (Fig. S3),
(b) increased the glycolytic ﬂux (Fig. 4B) correlating with increased
HIF1-α, GLUT1, HKII and LDH contents (Fig. 6A); and (c) decreased
OxPhos ﬂux, glutaminolysis, ΔΨm (Figs. 4B and S2), and mitochondrial
protein contents (2OGDH, ND1, COXIV and ANT; Fig. 6B) versus
normoxia, in agreement with previous works [13].
Under normoxia, silencing of p53 to generate p53shMCF-7 cells
(a) induced signiﬁcant lowering in the NOXA, PUMA and TIGAR con-
tents, as expected (Fig. 6A); (b) led to higher glycolytic ﬂux (Fig. 4B)
correlating with higher levels of HIF-1α and glycolytic protein targets
(Fig. 6A); and (c) decreased OxPhos ﬂux, ΔΨm, and mitochondrial pro-
tein contents except for ANT (Fig. 6B), vs. parental MCF-7 cells. Under
hypoxia, silencing of p53 also led to higher glycolytic ﬂux (Fig. 4B), cor-
relatingwith enhanced HIF-1α and GLUT1 levels (Fig. 6A) vs. normoxia,
and as occurs in HeLa-L cells. On the contrary, hypoxia signiﬁcantly di-
minished the OxPhos ﬂux and ΔΨm in MCF-7 cells (Figs. 4B and S2)
vs. normoxia, like in HeLa-L cells.
PFT-α also lowered the endogenous phosphorylated p53 content in
MCF-7 cells (data not shown),which in turn decreasedOxPhos (from17
to 7 ± 2 ngAt O/min/mg cell protein; n = 3) and increased glycolysis
(from 14 to 20 nmol/min/mg cell protein; n = 1). The OxPhos and gly-
colysis ﬂuxes in MCF-7 cells treated with PFT-α were similar to those
found in p53shMCF-7 cells (Fig. 4B). These results indicate that, inde-
pendently of the O2 concentration, the lack of p53 promotes that
HIF1-α can tightly up-regulate the glycolytic ﬂux. On the other hand,
growth of MCF-7 and p53shMCF-7 cells under normoxia was similar
(Fig. S3) indicating the lack of p53 control on the MCF-7 cell cycle.
3.7. p53 antagonizes HIF-1α activity in HeLa-H cells
Under hypoxia, the over-expression of p53 in HeLa-H cells (Fig. 1A)
led to inhibition of the glycolytic ﬂux (Fig. 4B) and a lower HIF-1α con-
tent compared toHeLa-L. It has been established that HIF1-αdirectly in-
teracts with wild-type p53 [33] impairing HIF-1α associated functionssphorylated and non-phosphorylated p53, and p53-target TIGAR. Representative Western
R inHeLa-H cells after PFT-α treatment. (B) Cellular growth. Growth curve of HeLa-H cells
ormoxic conditions; empty symbols represent hypoxia (Hyp). aP b 0.05 vs. HeLa-H/Nor at
nd its glycolytic targets in HeLa-H cells after PFT-α (10 μM) treatment. Normalization vs.
Fig. 6. p53, p53-targets, HIF-1α and energy pathways-related proteins in MCF-7 and p53shMCF-7 cells (A) The ﬁgure shows a representative Western blot of p53, p53-protein targets,
HIF-1α and its glycolytic-related proteins in MCF-7 and p53shMCF-7 cells cultured under normoxia (Nor, 21% O2) and 24 h hypoxia (Hyp, 0.1% O2); double normalization vs. actin and
normoxia was performed. n = 3, aP b 0.01 vs. MCF7; bP b 0.05 vs. MCF7. (B) Representative Western blot of OxPhos-related proteins MCF-7 and p53shMCF-7 cells under normoxia
(Nor, 21% O2) and 24 h hypoxia (Hyp, 0.1% O2), double normalization vs. actin and normoxia was performed. n = 3, aP b 0.01 vs. MCF7.
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latory mechanism of the p53 function, was evaluated in HeLa-H cells
under both normoxia and hypoxia. p53 was indeed detected in immu-
noprecipitates with HIF-1α antibody of normoxic (mildly) and hypoxic
(strongly) HeLa-H cells (Fig. 7). Immunoprecipitation with IgG1
(control antibody) of HeLa-H cells did not result in p53 or HIF-1α co-
precipitation (Fig. 7). Similarly, immunoprecipitation with HIF-1α anti-
body of normoxic or hypoxic HeLa-L cells did not result in p53
co-precipitation (Fig. 7). Then, it seemed that p53 may interfere
with the HIF-1α function onlywhen a relatively high content is reached
(in HeLa-H cells) but not with a negligible level (in HeLa-L cells).Fig. 7. Formation of p53-HIF-1α complexes in HeLa-H cells. Representative co-immuno-
precipitation blots of p53 and HIF-1α. Protein A-agarose beads were overnight preincu-
bated at 4 °C with HIF-1α antibody or IgG. Then, the beads were further incubated with
RIPA buffer permeabilized cells for 90 min at 4 °C. Thereafter, the bead-cell mixtures
were centrifuged. The supernatants containing unbound proteins (INPUT) were removed,
whereas the sedimentswere heated to release the bead-bound proteins (COMPLEX). Both
fractions, COMPLEX and INPUT, were subjected to Western blotting with antibodies
against HIF-1α, followed by anti-p53. n = 3 different preparations. Abbreviations: Nor,
normoxia; Hyp, hypoxia.3.8. p53-induced mitophagy activation in hypoxic HeLa-H cells
It has been documented that acute hypoxia (24 h) activates mito-
chondrial degradation (mitophagy) in several tumor cell lines such as
Hek-293, MDA-MB231, U87, U373, U251, and ZR-75 [35]. Therefore, to
assess the hypothesis that the harmful effect of hypoxia on OxPhos of
HeLa-H cells was mediated by p53-regulated mitophagy, several key
proteins of this process as well as the formation of autophagic vesicles
were determined in HeLa-L and HeLa-H cells as well as in MCF-7 andp53shMCF-7 cells. Indeed, increased contents in the BNIP3 mRNA
(Table S2) as well as in the protein contents of BNIP3, Atg3 (hypoxia)
and LAMP1 were observed for HeLa-H cells (vs. HeLa-L cells; Fig. 8A).
Fig. 8. Autophagy activation in HeLa-L and HeLa-H cells (A) Representative Western blot of autophagy and OxPhos-related-protein contents in HeLa-L and HeLa-H cells under normoxia
(Nor, 21%O2) and 24h-acute hypoxia (Hyp, 0.1%O2). n=3, aP b 0.01 vs. HeLa-H, bP b 0.05 vs. HeLa-H. (B) ConfocalmicroscopyofHeLa-L andHeLa-H cells exposed to hypoxia (0.1%O2) for
24 h. Both cell types were harvested, washed and loadedwith mito-tracker green (MTG, 500 nM) and lysotracker red (LTR,500 nM) for 60min at 37 °C in complete DMEMmedium. The
arrows indicate themitophagy incidence (co-loading) in each image; n= 25 different cells. (C) The relativeMTG and LTR-ﬂuorescence intensities of loaded-HeLa-L and HeLa-H cells are
plotted. aP b 0.01; bP b 0.05 vs. Nor, n = 25. Abbreviations: AFU, arbitrary ﬂuorescence units; Foxo3a, Fork head transcription factor O class; BNIP3, BCL2/adenovirus E1B
protein—interacting protein 3; Atg3, autophagocytosis associated protein 3; LAMP1, lysosome-associated membrane protein 1.
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well as BNIP3 and Atg3 (data not shown) was observed in MCF-7 cells
(vs. p53shMCF-7 cells) under normoxic and particularly under hypoxic
conditions. The phosphorylation (i.e., inactivation) of Foxo3a was evi-
dent in HeLa-H cells under normoxic conditions as it has been demon-
strated in mouse embryonic p53+/+ ﬁbroblasts [36]; however, after
the hypoxic stress, inactivated Foxo3a decreased by 38% correlating
with autophagy activation (Fig. 8A). Moreover, hypoxia induced a sig-
niﬁcant increase in the contents of the mitophagic proteins in HeLa-H
cells (vs. normoxia), except for P-Foxo3a, but not in HeLa-L cells
(vs. normoxia), except for LAMP1.
The mitophagy activation was also assessed by determining the
co-localization of mitochondria inside lysosomes by confocal microsco-
py (Fig. 8B). Under normoxia, higher contents of mitochondria andlysosomes were observed in HeLa-H cells compared to HeLa-L, but
mitochondria/lysosomes co-localization was not detected (Fig. 8B). On
the contrary, although hypoxia increased mitochondria/lysosome co-
localization in both HeLa cell types, the number of co-localizations
was greater in HeLa-H cells, corresponding with higher lysosomes con-
tent (N 50% vs. HeLa-L) and lower mitochondrial content (b80% vs.
HeLa-L) (Fig. 8C).
4. Discussion
4.1. Normoxia, tumor energy metabolism and p53 levels
Most of the previous studies on p53 and cancer energy metabolism
have been performed under normoxic conditions assessing the contents
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gene transcripts [6,7], all which however are not always indicative of
pathway functionality. Functions should be directly evaluated. On the
other hand, the glycolytic and OxPhos ﬂuxes have been determined
from total lactate production [3,6,9] and total O2 consumption [7,8], re-
spectively, without correcting for glutaminolysis-derived lactate, and
extra-mitochondrial and mitochondrial O2 uptake not associated to
OxPhos. In the present study, glycolytic ﬂux was properly determined
by adding 2DG, a glycolytic inhibitor, whereas OxPhos ﬂux was accu-
rately determined from total O2 consumption by adding oligomycin, a
speciﬁc and potent inhibitor of ATPS. Using these straightforward
biochemical strategies, the p53 contribution to energy metabolism
regulation could be comprehensively analyzed.
4.1.1. p53 activates mitochondrial function in normoxic conditions without
affecting glycolytic metabolism
The over-expression of p53 in HeLa-H cells brought about, under
normoxia, decreasedGLUT1 andGLUT3 protein levels aswell as a signif-
icant increment in TIGAR, the latter leading to diminished levels of the
PFK-1 activator Fru2,6BP. Similarly, p53 overexpression in HCT116 and
U2OS tumor cells correlated with a signiﬁcant diminution in gene ex-
pression and protein contents of GLUT1, GLUT3, PGAM, and Fru2,6BP
[3,5,6]. Although the transcriptional glycolytic activator HIF-1α and its
target LDH-A signiﬁcantly increased in HeLa-H cells, no changes were
observed in their HKII and PFK1 contents aswell as glycolytic ﬂux versus
HeLa-L cells. These results suggested that the glycolytic ﬂux was not in-
creased because the activities of the main controlling steps (i.e., GLUT,
HK, HPI) were not simultaneously enhanced [16]. A mechanistic expla-
nation for this behavior is that the interaction between p53 and HIF-1α
prevented glycolytic gene up-regulation by free HIF-1α [37].
On the other hand, the increased OxPhos ﬂux induced by the higher
p53 content in HeLa-H cells under normoxia correlated with the higher
OxPhos ﬂux of MCF-7 cells vs. that of p53shMCF-7 cells, indicating that
the presence of functional p53 leads to the activation of mitochondrial
metabolism through enhancing OxPhos protein contents, total oxygen
consumption, and ΔΨm. The stimulation of the total cellular oxygen
consumption in HeLa-H cells (37.5%), vs. HeLa-L cells, correlated
with a similar increment in the total oxygen consumption found in
p53(+/+) human colon cancer HCT116 cells compared to p53(−/−)
-HCT116 cells [7]. The enhanced OxPhos capacity in HeLa-H cells
under normoxia correlated with the increased levels of both p53
and HIF-1α. However, HIF-1α has no regulatory role on the OxPhos
machinery, except for up-regulation of PDK and one COX small subunit
[38,39], which have a minor impact in the control of OxPhos. Thus,
HIF1α− independent mechanisms are most likely involved in the p53
up-regulation of OxPhos in normoxia. The activation of OxPhos by p53
may be associated with the trans-activation (COX, glutaminase-L) and
repression (PDK2) of several genes coding for mitochondrial enzymes
[9,40].
4.1.2. p53 sensitizes tumor cell growth to anti-mitochondrial drugs
The notion that HeLa-H cells became highly dependent on themito-
chondrial function under normoxia (i.e., OxPhos contribution to cell ATP
supply was higher than 80%) was further supported by the marked
effect of anti-mitochondrial inhibitors on tumor cell proliferation,
which has also been demonstrated for other oxidative cancer cell lines
[41–43]. Interestingly, Cas-IIgly showed higher potency to abolish
cervix cancer cell growth than α-TEA, α-TOS and oligomycin. Cas-IIgly
potency on tumor cells is very likely associated with its multi-target
effect. Cas-IIgly is also a more water-soluble molecule than the other
three drugs. Relatively low doses of Cas-IIgly promote apoptosis, ROS
burst, mitophagy activation and decreased anti-oxidant system in dif-
ferent tumor cell lines such as HeLa, CHP-212 neuroblastoma, and C6
glioma with apparent negligible effects on non-tumor cells [44].
p53 arrests the cell cycle inﬁbroblasts andHCT116 colon cancer cells
growing as xenografts [33]. However, this p53 role was not evident inHeLa-H cells growing in bi-dimensional cultures under normoxia, in
agreement with data described for other aggressive carcinomas
(p53+/+ HCT116 colon and A549 lung) cultured as monolayers [34,45,
46]. The mechanisms associated with the lack of p53 effect on the
normoxic growth of 2D-cultured cells have not been elucidated. How-
ever, high glucose concentrations (≥10 mM), like those commonly
used in standard tumor cell cultures, increase the expression of several
genes (cyclins A1 and E2; and cell cycle factor E2F) involved in the acti-
vation of the cell cycle in tumor cell lines including those containing
p53-wild type levels such as MCF-7 cells [47]. Thus, the high glucose
content (25 mM) used in the culture media of HeLa and MCF-7 cells
probably counteracted the inhibitory effect of p53 on cellular
proliferation.
4.2. Hypoxia, tumor energy metabolism and p53 levels
4.2.1. p53 sensitizes HeLa cells to hypoxia-induced cellular death
After 24 h hypoxia, p53 promoted a further signiﬁcant diminution in
HeLa-H cellular density, whichwasmediated by autophagy as it has also
been reported for p53-containing glioblastoma (U87, U373); human
embryo kidney (HEK293), and breast (MDA-MB-231, ZR75) carcinoma
cells [35]. Apoptosis was not detected in HeLa-H cells after 24 h hypoxia
as similarly documented for MDA-MB-231, ZR75 and lymph node
(H1299) cells [35,48]. Although the mechanism associated with this
presumed p53 protection against apoptosis has not been elucidated, it
has been documented for human ﬁbroblasts, which contain functional
p53, an enhanced DNA repair capacity and increased mRNA synthesis
after UV light exposure compared with p53-deﬁcient ﬁbroblasts [49].
After 48 h hypoxia, autophagy plus apoptosis appeared to contribute
to the signiﬁcant cellular death observed in both HeLa cell types.
4.2.2. p53 decreases the glycolytic and OxPhos metabolism in
hypoxic conditions
The role of p53on cancer cell energymetabolismunder hypoxic con-
ditions has not been elucidated. Previous studies have demonstrated
that severe hypoxia (0.1%O2, 24 h) decreases themitochondrial function
in MCF-7 and HeLa carcinomas [13], and other human cancer cells, cor-
relating with the arrest of cell proliferation [50]. On the contrary, severe
hypoxia promotes enhanced glycolytic protein and HIF-1α contents,
enzyme activities and ﬂux in many cancer cell lines [25,51].
This apparently common energy metabolism pattern was here
reproduced by MCF-7 cells, in which hypoxia decreased OxPhos and
increased glycolysis. Down-regulation of p53 in p53shMCF-7 cells
avoided depression of OxPhos under hypoxia, whereas glycolysis was
still stimulated. Likewise, HeLa-L cells exhibited unaltered OxPhos and
increased glycolysis under hypoxia. Indeed, hypoxia slightly (10–20%)
diminished in HeLa-L cells the contents of only a few mitochondrial
enzymes (COXIV and ATPS), whereas for others no changes (ND1,
PDH) or even increments (GA-L, ANT, 2OGDH) were attained.
In contrast, the over-production of total and phosphorylated p53 in
HeLa-H cells led to depression of both OxPhos and glycolysis under
hypoxia, correlating with a negligible up-regulation of HIF-1α. The
treatment with PFT-α allowed these cells to increase both OxPhos and
glycolysis under hypoxia because PFT-α prompted decreased phos-
phorylated p53 (90%) and increased HIF-1α (3-times) levels, thus
reverting to a phenotype similar to that of HeLa-L cells. In consonance,
hypoxia induced in HeLa-H cells a decrease of 30–75% in the contents
of mitochondrial proteins (ND1, COXIV, PDH, 2OGDH, ATPS and ANT)
except for GA-L.
Therefore, HeLa-H cells were unable to increase the contents of
free HIF-1α and its glycolytic protein targets because p53 strongly
interacted with it. In addition, it appeared that p53 strongly down-
regulated OxPhos under hypoxia through HIF1α-independent mecha-
nisms. Glycolysis can also be moderately down-regulated by p53
under hypoxia only when high levels of this transcriptional factor are
present; however, at low or negligible levels such as those found in
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up-regulation of glycolysis induced by hypoxia (and HIF-1α).
LikeHIF-1α, p53 is stabilized and over-expressed under hypoxia [21,
52]. The mechanism involved in the p53 stabilization by hypoxia is not
well-understood, although it has been proposed that p53 directly inter-
acts with HIF-1α inducing p53 stabilization [53] and its endogenous ac-
cumulation [33]. In addition, it has been suggested that the p53/HIF-1α
interaction diminishes the HIF-1α up-regulation of glycolysis. As the
p53 content was higher (4-times vs. normoxia) in HeLa-H cells than in
MCF-7 cells (1.8-fold vs. normoxia; [13]), it seemed that p53was unable
to fully blockHIF-1α inMCF-7 cells. To test this hypothesis, co-immuno-
precipitation assays were performed in hypoxic HeLa-L and HeLa-H
cells (Fig. 7). Speciﬁc interaction betweenHIF-1α and p53was observed
in HeLa-H cells but not in HeLa-L, indicating that the formation of p53-
HIF-1α complexes promoted HIF-1α loss-of-function, mainly under
hypoxic conditions. As a control, no interaction of p53 and/or HIF-1α
with IgG1 was observed, supporting a speciﬁc HIF-1α/p53 complex
formation.
The severe decrease in OxPhos, glycolysis and cellular growth in
HeLa-H cells under hypoxia suggested a possible cytotoxic effect in-
duced by a high functional level of p53. However, the PFT-α treatment
of HeLa-H cells restored, under hypoxia, the glycolysis and OxPhos
ﬂuxes and elicited an increase in the HIF-1α level and activity, without
modifying the high p53 total content. Then, it seemed that the p53 reg-
ulatory effects on the energy metabolism pathways were not related to
synergistic cytotoxicity with hypoxia.
4.2.3. Elucidating the mechanism associated with the p53-induced
differential OxPhos response towards hypoxia in HeLa-H cells
Several mechanisms could be involved in the OxPhos impairment in-
duced by hypoxia in the presence of high p53 levels. For instance, in-
creased mitochondrial ROS levels induced by hypoxia exert deleterious
effects on mtDNA; as mtDNA encodes subunits of OxPhos enzymes, the
oxidative stress-inducedmtDNAdamagemay impair OxPhos functioning
[54]. In addition, it has been described that p53 down-regulatesMnSOD2Fig. 9. The interaction p53-HIF-1α under hypoxia induces loss of HIF-1α function in HeLa-H cel
p53 stimulates autophagy progression for mitochondrial digestion. Abbreviations: HRE, hypoxgene expression diminishing protein content and activity in MCF-7 cells
[55], or up-regulates MnSOD2 increasing activity in lymphoblasts and
ﬁbroblasts [56]. Moderate or severe hypoxia (0.1–1% O2 for 8–24 h) per
se activates the degradation of several organelles including mitochondria
[57], in cancer cells with high p53 levels such as MCF-7 and intrahepatic
cholangiocarcinoma cells [58], in order tomaintainnutrients supply. Like-
wise, the present study demonstrates that the hypoxia-induced autopha-
gy in HeLa cells was further enhanced by the presence of high p53 levels,
contributing to the OxPhos suppression in these conditions.
It has also been demonstrated that high p53 levels (a) down-
regulates [59,60] several transcription factors associated with the de
novo synthesis of respiratory chain components (p32 and H-RAS),
β-oxidation (PGC-1α) and mitochondrial biogenesis (c-MYC) [61];
and (b) binds to and inactivates mTERF2, which is involved in the up-
regulation of OxPhos [62]. As p53 is further activated under hypoxia,
these two OxPhos-repressing mechanisms might become active under
hypoxic conditions. A decreased OxPhos under hypoxia in cells with
high p53 could be related to apoptosis induction [19], as it has been re-
ported for p53 overexpressed-MCF-7 cells [63], colon cancer cells
(RKO), lung cancer (NCI-H1299) and transformed ﬁbroblasts (MEFS)
[64]. However, apoptotic onset was not observed in HeLa-H cells. More-
over, it has been demonstrated in lymphoid andmyeloid cells with reg-
ular p53 contents that radiation promotes activation of several genes
associated to apoptotic onset. In contrast, in ﬁbroblasts alsowith regular
p53 content, radiation promotes cell cycle arrest with no associated cell
death [49,reviewed in 65]. Then, it seems that p53 overexpression is not
always linked to apoptosis activation because not all genes associated
with p53-dependent apoptosis are turned on at the same time to induce
DNA damage [65]. An alternative explanation of the severe OxPhos
depression under hypoxia of HeLa-H and MCF-7 cells, which might
not involve downregulation by high p53, is that cells with high OxPhos
rates aremore susceptible to O2 depletion because they express OxPhos
enzymes with higher afﬁnities, particularly respiratory complex IV.
However, data on differential expression of OxPhos isoenzymes have
not been described.ls. High p53 content interacts with HIF-1α avoiding glycolytic activation. In turn, excess of
ia responsive elements; Lac, lactate; Pyr, pyruvate; VHL, von-Hippel Lindau protein.
3277I. Hernández-Reséndiz et al. / Biochimica et Biophysica Acta 1853 (2015) 3266–32785. Concluding remarks
The bioenergetics analysis of two tumor lines with essentially
identical genetic background, but different p53 levels, revealed a dual
p53 regulatory behavior on mitochondrial and glycolytic metabolism,
depending on the O2 level (Fig. 9). Under normoxia (i.e., condition
observed for solid tumor cells near to blood vessels), p53up-regulatesmi-
tochondrial function being OxPhos the predominant ATP supplier. In this
condition, p53-high cells were highly sensitive to anti-mitochondrial
drugs. Under hypoxia (i.e., condition observed for solid tumor cells dis-
tant from blood vessels), p53 down-regulates OxPhos and activates
mitophagy. In consequence, glycolysis becomes the predominant ATP
supplier (Fig. 9).
The analysis of energy metabolism in mutation-free p53 cells facili-
tates the elucidation of the p53 regulatory mechanisms on OxPhos
and glycolysis, and provides a platform for understanding the effects
on energy metabolism of the numerous p53 mutations.
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